Clinical trial
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous…
NCT00445965 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00445965 |
|---|---|
| Title | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer |
| Official title | Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer |
| Intervention type | Genetic, Other, Radiation |
| Interventions | DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8 |
| Enrollment | 78 |
| Start date | Jan 1, 2006 |
| Primary completion | Feb 1, 2023 |
| Completion | Feb 1, 2023 |
| First posted | Mar 9, 2007 |
| Last update posted | Apr 4, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: